Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 464 results for blood monitoring

  1. Familial hypercholesterolaemia (QS41)

    This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.

  2. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

  3. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

  4. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

  5. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

  6. Lactate level for monitoring severity of shock:- Is lactate monitoring in patients with major trauma clinically and cost effective?

    NG39/2 Question Lactate level for monitoring severity of shock:- Is lactate monitoring in patients with major trauma...

  7. HemaClear for bloodless surgical field during limb surgery (MIB187)

    NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .

  8. Apremilast for treating active psoriatic arthritis (TA433)

    Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.

  9. Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.

  10. Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)

    Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.

  11. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

  12. Reducing sexually transmitted infections (NG221)

    This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.

  13. Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)

    This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women, trans men and non-binary people with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support that is given, to limit the psychological impact of their loss.

  14. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)

    This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.

  15. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.